SCHEMBL1237720

SCHEMBL1237720

Cc1ccc(O)c(Cn2c(NC3CCN(C)CC3)nc3ccc(CNc4cc(Cl)cc(Cl)c4)cc32)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.41
KCNH2 Q12809 7/20 0.40
NR4A2 P43354 2/20 0.40
SSTR5 P35346 8/20 0.39
LMNA P02545 3/20 0.37
GAA P10253 2/20 0.37
EED O75530 2/20 0.37
HRH1 P35367 2/20 0.37
HRH4 Q9H3N8 2/20 0.37
HTT P42858 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
MLNR O43193 1/20 0.37
CACNA1F O60840 1/20 0.37
USP2 O75604 1/20 0.37
ABCB11 O95342 1/20 0.37
EGFR P00533 1/20 0.37
HLA-A P04439 1/20 0.37
ERBB2 P04626 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8292644 0.86 KCNH2 (0.45) SOS1KCNH2NR4A2SSTR5LMNA
SCHEMBL8294206 0.85 KCNH2 (0.43) SOS1KCNH2NR4A2SSTR5LMNA
SCHEMBL1238600 0.85 SCD (0.40) KCNH2NR4A2SSTR5HRH4MAPT
SCHEMBL12909078 0.85 KCNH2 (0.43) SOS1KCNH2NR4A2SSTR5LMNA
SCHEMBL1238593 0.84 KCNH2 (0.43) KCNH2NR4A2SSTR5LMNAGAA
SCHEMBL8294761 0.83 KCNH2 (0.42) KCNH2NR4A2SSTR5LMNAGAA
SCHEMBL8284394 0.83 KCNH2 (0.42) KCNH2NR4A2SSTR5LMNAGAA
SCHEMBL8294929 0.82 KCNH2 (0.41) SOS1KCNH2NR4A2SSTR5LMNA
SCHEMBL1237484 0.82 KCNH2 (0.41) KCNH2NR4A2SSTR5LMNAGAA
SCHEMBL8293191 0.81 KCNH2 (0.40) KCNH2NR4A2SSTR5LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278455-B2 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication JANSSEN PHARMACEUTICA N.V. (BE) 2012-10-02 US disclosed
EP-1697347-B1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARM LTD (IE) 2011-02-23 EP disclosed
US-20090062278-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION JANSSEN SCIENCES IRELAND UC (IE) 2009-03-05 US disclosed
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication BONFANTI JEAN-FRANCOIS 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SUB1, HYOU1 SOS1 2605/4885KCNH2 368/4885NR4A2 331/4885
US-20090062278-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYC1, SUB1 SOS1 2331/4885KCNH2 419/4885NR4A2 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.